New Delhi: Pharma major Lupin Limited [BSE: 500257 | NSE: LUPIN] reported its financial performance for the quarter ending June 30, 2026. These unaudited results were taken on record by the Board of Directors at a meeting.
Amt in INR Mn
| Particulars | Quarter | ||||
| Q1 FY2027 | Q1 FY2026 | YoY Growth % | Q4 FY2026 | QoQ Growth % | |
| Sales | 82,172 | 61,638 | ↑ 33.3% | 73,919 | ↑ 11.2% |
| EBITDA* | 25,799 | 18,063 | ↑ 42.8% | 26,263 | ↓ 1.8% |
| EBITDA Margin (%)* | 31.4% | 29.3% | ↑ 210 bps | 35.5% | ↓ 410 bps |
| PBT | 20,174 | 14,155 | ↑ 42.5% | 19,280 | ↑ 4.6% |
| PAT | 14,170 | 12,215 | ↑ 16.0% | 14,687 | ↓ 3.5% |
*Includes forex & other income
Income Statement Highlights – Q1 FY2027
v Gross Profit was up 39.5% at INR 61,280 Mn from INR 43,919 Mn in Q1 FY2026, with a gross margin of 74.6%.
v Personnel cost was 16.8% of sales at INR 13,830 Mn compared to INR 10,830 Mn in Q1 FY2026.
v Manufacturing and other expenses were 28.5% of sales at INR 23,412 Mn compared to INR 17,720 Mn in Q1 FY2026.
v PBT at INR 20,174 Mn was 24.6% of sales, up 42.5% YoY from INR 14,155 Mn in Q1 FY2026.
v Investment in R&D for the quarter was INR 6,077 Mn (7.4% of sales).
Balance Sheet highlights
v Operating working capital was INR 82,596 Mn as on June 30, 2026. Operating days for quarter stood at 90 days.
v Capital Expenditure for the quarter was INR 2,786 Mn.
v Net Debt as on June 30, 2026, stands at INR -28,308 Mn.
v Net Debt Equity as on June 30, 2026, stands at -0.12.
Nilesh Gupta, Managing Director, Lupin Limited said “We are pleased to begin FY27 with a strong performance, driven by robust growth across our key markets and continued improvement in profitability. Our focus on execution, operational excellence, and sustained investments in technology and innovation continue to strengthen the business and position us for sustainable, profitablegrowth over the long term”.
Amt in INR Mn
| Particulars | Q1 | % of | Q1 | % of | YoY | Q4 | % of | QoQ |
| FY2027 | sales | FY2026 | sales | Growth % | FY2026 | sales | Growth % | |
| Sales
Other operating income |
82,172
597 |
100.0%
0.7% |
61,638
1,045 |
100.0%
1.7% |
↑ 33.3%
↓ 42.9% |
73,919
828 |
100.0%
1.1% |
↑ 11.2%
↓ 27.9% |
| Total Revenue from
operations |
82,769 | 100.7% | 62,683 | 101.7% | ↑ 32.0% | 74,747 | 101.1% | ↑ 10.7% |
| Material cost | 20,892 | 25.4% | 17,719 | 28.7% | ↑ 17.9% | 18,516 | 25.0% | ↑ 12.8% |
| Gross Profit (excludingOther operating income) | 61,280 | 74.6% | 43,919 | 71.3% | ↑ 39.5% | 55,403 | 75.0% | ↑ 10.6% |
| Employee cost | 13,830 | 16.8% | 10,830 | 17.6% | ↑ 27.7% | 12,427 | 16.8% | ↑ 11.3% |
| Manufacturing & Other expenses | 23,412 | 28.5% | 17,720 | 28.7% | ↑ 32.1% | 22,093 | 29.9% | ↑ 6.0% |
| Other Income | 1,303 | 1.6% |
